Blue Fin Capital Inc. Acquires 151 Shares of Stryker Co. (NYSE:SYK)

Blue Fin Capital Inc. grew its stake in Stryker Co. (NYSE:SYK) by 1.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,034 shares of the medical technology company’s stock after purchasing an additional 151 shares during the quarter. Stryker makes up approximately 0.7% of Blue Fin Capital Inc.’s investment portfolio, making the stock its 26th largest holding. Blue Fin Capital Inc.’s holdings in Stryker were worth $3,973,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in SYK. Elefante Mark B bought a new stake in Stryker in the 4th quarter valued at about $337,000. Chicago Capital LLC boosted its stake in shares of Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock valued at $70,228,000 after buying an additional 5,841 shares during the period. Appleton Partners Inc. MA grew its position in Stryker by 5.0% during the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock worth $10,521,000 after buying an additional 1,400 shares in the last quarter. Metis Global Partners LLC increased its stake in Stryker by 10.2% during the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock worth $6,064,000 after acquiring an additional 1,561 shares during the period. Finally, Fred Alger Management LLC raised its holdings in Stryker by 415.8% in the 4th quarter. Fred Alger Management LLC now owns 24,011 shares of the medical technology company’s stock valued at $8,664,000 after acquiring an additional 19,356 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on SYK. Sanford C. Bernstein set a $450.00 price target on Stryker in a research note on Monday, May 5th. JPMorgan Chase & Co. raised their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a report on Tuesday, March 4th. Wells Fargo & Company lifted their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, Citigroup restated a “buy” rating and set a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $427.05.

Stryker Stock Performance

Stryker stock opened at $380.02 on Thursday. The business has a 50 day moving average of $367.95 and a 200-day moving average of $375.92. The company has a market capitalization of $145.05 billion, a P/E ratio of 48.97, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.50 EPS. On average, equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker’s dividend payout ratio is currently 45.41%.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.